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Abstract
Background: There are many examples of physicians using treatments inappropriately, despite
clear evidence about the circumstances under which the benefits of such treatments outweigh their
harms. When such over- or under- use of treatments occurs for common diseases, the burden to
the healthcare system and risks to patients can be substantial. We propose that a major contributor
to inappropriate treatment may be how clinicians judge the likelihood of important treatment
outcomes, and how these judgments influence their treatment decisions. The current study will
examine the role of judged outcome probabilities and other cognitive factors in the context of two
clinical treatment decisions: 1) prescription of antibiotics for sore throat, where we hypothesize
overestimation of benefit and underestimation of harm leads to over-prescription of antibiotics;
and 2) initiation of anticoagulation for patients with atrial fibrillation (AF), where we hypothesize
that underestimation of benefit and overestimation of harm leads to under-prescription of warfarin.
Methods: For each of the two conditions, we will administer surveys of two types (Type 1 and
Type 2) to different samples of Canadian physicians. The primary goal of the Type 1 survey is to
assess physicians' perceived outcome probabilities (both good and bad outcomes) for the target
treatment. Type 1 surveys will assess judged outcome probabilities in the context of a
representative patient, and include questions about how physicians currently treat such cases, the
recollection of rare or vivid outcomes, as well as practice and demographic details. The primary
goal of the Type 2 surveys is to measure the specific factors that drive individual clinical judgments
and treatment decisions, using a 'clinical judgment analysis' or 'lens modeling' approach. This survey
will manipulate eight clinical variables across a series of sixteen realistic case vignettes. Based on
the survey responses, we will be able to identify which variables have the greatest effect on
physician judgments, and whether judgments are affected by inappropriate cues or incorrect
weighting of appropriate cues. We will send antibiotics surveys to family physicians (300 per
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survey), and warfarin surveys to both family physicians and internal medicine specialists (300 per
group per survey), for a total of 1,800 physicians. Each Type 1 survey will be two to four pages in
length and take about fifteen minutes to complete, while each Type 2 survey will be eight to ten
pages in length and take about thirty minutes to complete.
Discussion: This work will provide insight into the extent to which clinicians' judgments about the
likelihood of important treatment outcomes explain inappropriate treatment decisions. This work
will also provide information necessary for the development of an individualized feedback tool
designed to improve treatment decisions. The techniques developed here have the potential to be
applicable to a wide range of clinical areas where inappropriate utilization stems from biased
judgments.
Background
The problem of inappropriate use of existing treatments
represents a significant challenge for knowledge transla-
tion (KT) researchers. There is mounting evidence that a
wide variety of treatments are either under- or over-used,
and that this inappropriate use causes significant burden
to health-care systems. For example, cardiovascular com-
plications are the most common cause of death among
diabetics, yet despite clear evidence of benefit, less than
50% receive angiotensin-converting enzyme (ACE) inhib-
itors [1]. In contrast, other work has shown that benzodi-
azepines are over-used, despite clear guidelines that they
should be used cautiously [2]. At a more general level,
studies from the US and the Netherlands suggest that
approximately 30 to 40% of patients do not receive care
according to current scientific evidence and approxi-
mately 20 to 25% of care provided is either not needed or
potentially harmful [3-6].
KT frameworks that characterize the process of translating
new evidence into practice change typically recognize the
individual practitioner as a key component in the process
[7,8]. Indeed, 80% of interventions have focused on the
individual practitioner (e.g., continuing medical educa-
tion, educational outreach, audit and feedback, remind-
ers) [9]. Despite all this research, the options of what
interventions to choose, and how to evaluate them, have
been driven more by investigator preference than by
explicit empirical or theoretical rationale. Any such
rationale would need to consider, at a minimum, what is
known about how individuals make decisions. The cur-
rent project will begin the work of applying existing cog-
nitive psychological theory to the problem of changing
physician behaviour at the level of the individual practi-
tioner.
Theoretical basis for physician behaviour change: human 
judgment and decision making
Most KT frameworks recognize the individual practitioner
as a key component in the process of practice change,
because it is the practitioner who ultimately makes diag-
nosis and treatment decisions. This is particularly true in
areas where physician autonomy is high, as is the case
with many kinds of pharmaceutical treatment. In these
situations, it is ultimately the individual practitioner who
decides whether or not to prescribe medicines for a
patient. In terms of understanding how individuals
change their treatment behaviour, one area of psycholog-
ical theory has been under-utilized. Cognitive psychology,
and in particular the judgment and decision-making liter-
ature, has developed both theoretical frameworks and
methods that could be exploited to develop and improve
KT interventions aimed at the individual practitioner [10-
12]. The current work hinges on two fundamental claims
that have their empirical foundation in the judgment and
decision-making literature.
Claim one: physicians' treatment decisions often depend 
on their judgments of treatment outcome probabilities
Judgment and decision making psychologists have pro-
posed a variety of models of how people make decisions.
These models range from "non-decision" behaviours, per-
formed reflexively and without considering specific case
features or alternative courses of action, to the hyper-
rational (and unpragmatically complex) tenets of formal
decision analysis [13]. Many psychologists now believe
that human decision making often falls somewhere
between these two extremes. Many decisions will incorpo-
rate common elements, such as identifying decision
options and their possible outcomes, judging the likeli-
hood and value of these outcomes, and then combining
this information to make a decision [13]. Although errors
can occur with any of these elements [14], several lines of
evidence lead us to study errors in judgments of outcome
likelihood, and whether improving such judgments might
increase appropriate use of treatments. First, there is con-
siderable evidence showing that physicians have trouble
accurately judging the probability of important clinical
events and outcomes in a variety of clinical settings [15].
Second, several surveys have also suggested that physi-
cians make decisions about pharmaceutical treatment
according to their judgments of the likelihood of relevant
outcomes [16]. Third, a pilot study by the authors showed
that physicians use their judgments of treatment effective-Implementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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ness and adverse reaction probabilities to decide upon
treatment for congestive heart failure [15]. The two clini-
cal problems selected for this current study involve phar-
maceutical treatment decisions and share many
characteristics with the pilot study condition. However,
we will evaluate whether claim one holds true for these
two new clinical situations.
In short, changing physician treatment decisions may rest
on improving physicians' judgments of outcome proba-
bilities. One of the goals of this project is to determine
whether hypothetical treatment decisions involving two
pharmaceutical treatment decisions depend upon these
judged outcome probabilities.
Claim two: cognitive factors can cause errors in physician 
judgments of treatment outcome probabilities
There is clear evidence that physicians often make errors
when making diagnostic or prognostic judgments [17-
21], and that individual physicians [22] and groups of
physicians [23] vary in their ability to make these judg-
ments. Many of these errors have been attributed to "cog-
nitive biases", which can be defined as the tendency to
systematically over- or underestimate particular outcome
probabilities. An example of such a tendency is "ego bias",
which is the tendency to believe that one's own perform-
ance is likely to be better than average [24]. One study
showed that ego bias can lead to systematic errors in phy-
sicians' prognostic judgments for critically ill patients [4].
In addition to studying systemic errors or biases in the
thinking of decision makers, considerable work has
focused on cognitive 'heuristics'. These simple mental
rules-of-thumb very often produce accurate judgments
and are thus highly efficient [25,26]. However, in some
situations such shortcuts actually mislead and degrade
some diagnostic and prognostic judgments. For example,
the "availability heuristic" bases the judgment of a partic-
ular outcome probability on the ease with which one can
recall instances of similar outcomes [23]. Since vivid
events are often more easily recalled than mundane ones,
this heuristic could cause one to overestimate the likeli-
hood of unusual or bizarre cases and underestimate the
likelihood of more commonplace ones. For example, pre-
vious studies have shown that the availability heuristic
may affect physicians' diagnostic judgments for bactere-
mia [23]. One of the goals of the current work is to deter-
mine the extent to which cognitive heuristics such as
availability contribute to inappropriate use of treatments
by physicians.
Some cognitive factors might be expected to affect dispro-
portionately certain subsets of physicians. For example,
one study found that the "illusion of control", the ten-
dency to have too much faith in one's own ability to con-
trol future events [27,28], can explain why cardiologists
generally judge the probabilities of adverse outcomes due
to cardiac procedures to be lower than do other internists
[29]. Furthermore, less experienced decision makers may
be more likely to be influenced by indicators not reliably
associated with the outcome. For example, a cracking
sound at the time of an ankle injury is unrelated to the
presence of a fracture, yet many less experienced emer-
gency physicians report considering this indicator when
deciding whether to order radiography [30]. Examination
of the extent to which groups of decision makers differ in
their assessments of outcome probabilities and their rela-
tive susceptibility to different cognitive biases warrants
further study.
Examples of clinical therapies that are inappropriately 
utilized
This project will examine whether inappropriate treat-
ment decisions are associated with judged outcome prob-
abilities and judgment biases. Two clinical conditions
were selected; one in which treatment is generally over-
utilized, the other where it is under-utilized. We examine
both over- and under-utilization because changing an
existing, well-practiced behaviour (i.e. reducing the use of
over-utilized treatments) may require different change
mechanisms than beginning a new behaviour (i.e. adopt-
ing an under-utilized treatment). This proposal focuses on
two specific treatments: the over-prescription of antibiot-
ics for pharyngitis treatment, and the under-use of warfa-
rin (Coumadin) for treatment of chronic AF.
Our goal for both clinical conditions is to understand rela-
tionships between treatment decisions and judged proba-
bilities of 'outcomes'; i.e. the benefits and harms that
might stem from a given treatment. In the case of warfarin
treatment for AF, key outcomes will include stroke (fatal
or permanently disabling) and major hemorrhages (fatal,
intracranial, or other bleeds requiring hospitalization). In
the case of antibiotics for pharyngitis, relevant outcomes
include resolution of symptoms, local and systemic com-
plications from such infections (e.g., perotonsillar abscess
and glomerulonephritis), and complications of treat-
ment, such as adverse drug reactions (ADRs).
Under-use of warfarin (Coumadin) for treatment of AF
There are many documented examples of physicians fail-
ing to use treatments where the benefits clearly outweigh
the risks and costs. Such failures to use effective treat-
ments [31-41] can have major implications on health-
related costs and overall patient care [6], and guideline
developers argue that the detection of instances when
physicians fail to use treatments of proven effectiveness
should be a cornerstone of quality assessment [42].Implementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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One example of an underused effective treatment is anti-
coagulation with warfarin (Coumadin) for the treatment
of chronic AF. AF is a common cardiac arrhythmia, affect-
ing 5% of the population over the age of 65 [43,44]. While
AF increases the risk of stroke six-fold [45,46], use of the
anti-coagulant warfarin can substantially reduce that risk
[47]. However, there is evidence that despite its effective-
ness, anti-coagulants are only taken by 30–60% of appro-
priate patients. A variety of reasons for this under-use,
including those to do with its perceived outcome proba-
bilities by prescribing physicians [48-50], have been pro-
posed but never empirically tested. We will survey
samples of family physicians and internal medicine spe-
cialists about their practice of prescribing anti-coagulation
for people with AF.
Over-use of antibiotics for sore throat (pharyngitis)
Bacterial resistance to antibiotics has become a global
public health problem [51,52]. The over-use of antibiotics
by humans is clearly an important cause of this problem
[51], much of which can be attributed to the prescribing
practices of physicians [52]. One study found that physi-
cians prescribed antibiotics for between 57% and 74% of
patients with pharyngitis [53]. Yet, despite the widespread
use of antibiotics for pharyngitis, the literature shows very
little evidence of the effectiveness of these treatments in
terms of speed of symptom resolution or lower rates of
adverse events among patients with pharyngitis. While
some evidence may demonstrate effectiveness of narrow-
spectrum antibiotics among patients with high likelihood
of streptococcal pharyngitis [54-56], these benefits do not
appear to extend to the wider population of all patients
with pharyngitis. Furthermore, the use of broad spectrum
antibiotics for pharyngitis may be on the rise, yet there is
no evidence of any increased benefit of these antibiotics
over more narrow-spectrum choices [53,57,58].
Our review identified four studies that compared cepha-
losporins to penicillin, all of which showed no benefits
[59-62]. Five studies showed no evidence that extended-
spectrum macrolides produce any improvement over pen-
icillin V or erythromycin [63-68]. The one study compar-
ing amoxacillin/clavulinic acid to penicillin also failed to
show any benefits of the antibiotic [69]. No studies have
compared the use of any fluoroquinolone or broad-spec-
trum antibiotic to penicillin among patients with pharyn-
gitis. In short, the literature on treatment for pharyngitis
does not justify use of antibiotics on the general popula-
tion of patients with pharyngitis, and has failed to
uncover any evidence that broad-spectrum antibiotics
produce any additional benefit over narrow-spectrum
choices like penicillin. Previous interventions to reduce
antibiotic use have met with limited success. Some meth-
ods involving personalized feedback have been somewhat
effective, although these interventions are also labor-
intensive, costly and complex, with little known about the
extent to which the observed practice change is sustained
[70,71].
Hypotheses
We will examine the role of judged outcome probabilities
and judgment biases for two kinds of treatment decisions:
use of antibiotics for patients with pharyngitis, and use of
anti-coagulants for treatment of AF. The study will address
five specific hypotheses:
1. Physicians' decisions to use specific treatments depend
on their judgments of the likelihood of treatment out-
comes.
2. Physician judgments of the likelihood of treatment out-
comes will sometimes be inaccurate;
3. Specific judgment heuristics can account for some of
the inaccuracies of physician judgments of treatment out-
comes;
4. Predictable groups of physicians will be more apt to be
inaccurate in their judgments of treatment outcomes;
5. Judgment inaccuracies will stem from physicians
attending to cues that are unrelated to treatment out-
comes, and/or insufficiently attending to cues that are
related to outcomes.
Methods
Four surveys will be mailed to Canadian physicians, two
focused on the use of antibiotics for pharyngitis, and two
on the use of anti-coagulants for treatment of AF. For each
clinical condition, one survey (Type 1) will measure the
accuracy of judged probabilities of treatment-related out-
comes, while the other (Type 2) will use a series of realistic
case vignettes to determine what factors affect treatment
decisions.
Development of the various surveys will require us to per-
form the following tasks: systematically review the rele-
vant clinical literatures to identify the characteristics of
patients to whom the research results would generalize;
identify the important outcomes, good and bad, condi-
tional on treatment; develop evidence-based estimates of
the population rates of these outcomes conditional on
choice of treatment; and assess the evidence about patient
factors that may predict these outcomes. We will also
review the available evidence about factors that influence
physicians' decisions around use of the treatment. We will
construct and pilot test surveys to evaluate physicians'
judgments and decisions based on this work. These sur-
veys will be informed by pilot work done in the US on a
different range of clinical subspecialties.Implementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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Procedure
The primary goals of the Type 1 surveys will be to assess
physicians' perceived outcome probabilities (good and
bad) for different treatments, and to compare these per-
ceived probabilities to the real rates indicated by system-
atic reviews (hypothesis two). These goals will be achieved
by having physicians assess a hypothetical patient repre-
sentative of those included in the most important and rel-
evant RCTs of the target condition. The survey will assess
judged outcome probabilities, by asking physicians to
quantify the likelihood of various outcomes if a hundred
patients similar to this hypothetical patient were to be
treated. The Type 1 surveys will also ask physicians about
how they currently treat such cases, the recollection of rare
or vivid outcomes (hypothesis three), as well as practice
and demographic details.
The primary goals of the Type 2 surveys will be to measure
specific factors that drive individual clinician judgments
and treatment decisions (hypothesis five), and to deter-
mine whether individual physician judgments predict
treatment decisions (hypothesis one). These goals will be
achieved by having physicians consider sixteen realistic
case vignettes about hypothetical patients with the target
condition. Eight clinical variables will be varied systemat-
ically across the sixteen case vignettes using a partial facto-
rial design. For example, the manipulated variables in the
antibiotics vignettes could include factors related to clini-
cal outcomes (e.g. Centor criteria predicting strep: cough,
fever, tonsillar exudates, tender lymph nodes), as well as
non-predictive variables that might be perceived as pre-
dictive (e.g. age, sex, occupation). The vignettes will
prompt physicians to indicate what management decision
they would select for each clinical variable combination.
These responses will allow for the identification of which
variables have the greatest effect on physician judgments,
and whether such judgments are affected by non-predic-
tive cues or the unrealistic expectations of appropriate
cues.
Four surveys will be mailed to different random samples
of Canadian physicians. The pharyngitis surveys will be
administered to different samples of 300 family physi-
cians. Each warfarin survey will be administered to 300
family physicians and 300 internal medicine specialists;
this design reflects the fact that this clinical decision is
made by both groups of physicians. It will also allow us to
examine differences in decision making between two dif-
ferent disciplines (hypothesis four).
We therefore propose to mail four different surveys to a
total of 1800 physicians (1200 family physicians and 600
internal medicine specialists). The names, addresses, and
telephone numbers of these physicians will be obtained
from the Canadian Medical Association Directory and
membership lists of specialty organizations, such as the
Canadian College of Family Physicians and the Royal Col-
lege of Physicians and Surgeons of Canada. The sampling
population will be limited to English-speaking physi-
cians, since the detailed nature of the surveys would make
translation into French extremely time-consuming,
requiring a lengthy series of iterations of translation and
back-translation to ensure comparability between lan-
guages. Random selection from membership lists will
result in a sampling population that has approximately
the same ratio of physicians from all provinces and terri-
tories as in the membership list.
While considerable research has demonstrated the diffi-
culty of obtaining high response rates from physicians,
the members of this team have considerable experience in
doing so with comparable populations [15,30,72-74].
This project will employ the Dillman Tailored Design
Method for survey design and implementation, which is
one of the most widely used and tested surveying methods
[75]. A recent systematic review demonstrated that recom-
mendations of the Dillman method apply to surveys of
physicians [76]. In accordance with the design, an initial
pre-notification letter will be sent to all selected physi-
cians and the survey will follow one week later. A series of
three reminders and two replacement surveys will then be
mailed out to non-responders at two-week intervals. All
correspondences will be addressed to the individual phy-
sicians, and personally signed by the principal investiga-
tor.
The characteristics of the responders and non-responders
will be compared, to determine how the generalizability
of the survey results may be affected by response bias. This
physician-specific information will be obtained from the
membership lists used to derive the sampling population.
The Dillman method has previously been employed to
survey Canadian physician society lists, yielding response
rates in excess of 80% [77,78]. The Type 1 surveys will be
two to four pages in length and take approximately fifteen
minutes to complete. In contrast, the Type 2 surveys will
be eight to ten pages in length and take about thirty min-
utes to complete. There is extensive literature showing that
non-trivial financial incentives can improve physician sur-
vey response rates anywhere from 8.6% to 48.5% [76]. As
a result, a $20 incentive will be offered to all survey partic-
ipants who return a completed survey.
Data quality and data collection
Quality assurance procedures will be implemented to
ensure the integrity of the survey data collection [79,80].
A log record will be initiated and maintained to track the
study status of participants throughout the mailings of the
surveys. To ensure confidentiality, participants will beImplementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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assigned a code number for use on all subsequent study
documentation.
The survey data will be entered into SPSS. Upper and
lower limits will be set for each variable, allowing the
database program to detect and highlight logical and
range errors requiring correction. In order to assess data
entry accuracy, 10% of case records will be randomly
selected and re-entered. If this data check finds an error
rate greater than 1%, the accuracy of the data will be con-
sidered unacceptable and all cases will be re-entered and
re-assessed.
Analysis
Hypothesis one: physicians' decisions to use specific treatments 
depend on their judgments of the likelihood of treatment outcomes
This hypothesis will be evaluated using data from the
Type 2 surveys. After adjusting for covariates, data will be
examined to determine the extent to which individual
judged outcome likelihoods predict treatment decisions
across the sixteen cases. For example, physicians complet-
ing the Type 2 antibiotics survey will be asked to judge the
proportion of patients for whom sore throat pain would
resolve by day three if they 1) were given no antibiotic, or
2) were given penicillin. By subtracting the second value
from the first, we can determine the judged absolute
increase in likelihood of symptom resolution due to use
of the antibiotic. We will then determine the extent to
which differences in these outcome likelihood judgments
across cases predict differences in treatment decisions
(after controlling for additional factors such as demo-
graphic characteristics, specialty, practice setting, etc). The
analytic strategy for this hypothesis will rely on the use of
hierarchical or mixed model regression, which permits the
estimation of physician-specific coefficients and the inclu-
sion of physician-level covariates [81-83]. For example,
the analysis of the decision to treat with antibiotics could
be performed using a hierarchical multivariate regression
models for an individual physician, 'physician I'. This
model will take the form:
TRij = b0i + b1i Aij + b2i Bij + b3i Cij + error
where TRij represents how strongly physician i feels about
the patient's treatment in vignette j; b0i is a physician spe-
cific intercept; and Aij and Bij represent within- physician
covariates.
The second level of the model will describe variation
between physicians. This level will ordinarily assume that
the coordinates (b0, b1, b2, etc.) vary at random across
physicians. These coordinates measure the effect of the
components of A, B, and C within physician i. We will
also consider using models where the intercept and the
coefficients of A, B, and C are functions of physician char-
acteristics.
The hierarchical model will provide estimates of the phy-
sician-specific coefficients and components of variance.
The more elaborate models will also provide estimates of
coefficients describing inter-physician variability as a
function of physician characteristics (components of spe-
cialty, practice setting, etc). The model-fitting process will
use standard software for hierarchical and mixed models,
including subroutines from SAS, MLWin [83] and BUGS
[84].
Hypothesis two: physician judgments of the likelihood of treatment 
outcomes will sometimes be inaccurate
To evaluate this hypothesis, data from the Type 1 surveys
will be used to test whether judged outcome likelihoods
for a representative patient match best evidence from sys-
tematic reviews. For example, judged absolute increase in
resolution of symptoms due to antibiotics use will be
computed as described above (hypothesis one). This will
allow the comparison of judged estimates with the 95%
confidence intervals reported by these trials and tabula-
tion of the percentage of physicians that are outside the
95% confidence intervals (i.e. maintaining beliefs that
have been "ruled out" by the trials). We will display the
distribution of the physicians' judgments compared to the
trials' best estimate and surrounding 95% confidence
intervals.
Hypothesis three: specific judgment heuristics can account for some 
of the inaccuracies of physician judgments of treatment outcomes
Type 1 surveys will include questions on whether rare or
vivid outcomes had been seen by the physician in the pre-
vious year. The extent to which the answers to this ques-
tion affect judgment accuracy will be analyzed using an
approach similar to that for hypothesis one. Note, how-
ever, that there will only be one observation per physi-
cian, therefore hierarchical modeling will not be required.
This analysis will test whether experience of and memory
for rare, bizarre, or vivid outcomes (e.g. suppurative com-
plication of a streptococcal infection) affect the assess-
ment of the overall likelihood of such an outcome. The
response variable in the regression models will be the
assessment of the likelihood of outcome for the case pre-
sented in the Type 1 survey. Independent variables will
include physician characteristics (e.g. demographics, spe-
cialty, and practice setting) and the physicians' recollec-
tions of rare outcomes.
Hypothesis four: predictable groups of physicians will be more apt to 
be inaccurate in their judgments of treatment outcomes
This hypothesis will be addressed using data from the
Type 1 warfarin survey. The judged likelihood of out-
comes for each physician will be calculated, then com-Implementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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pared with the best evidence as indicated for hypothesis
two. After controlling for a variety of covariates (age, gen-
der, practice setting, etc.), the accuracy between the physi-
cians' specialty groups will be compared (family
physicians and internal medicine specialists). If groups
differ in accuracy after controlling for the covariates,
exploratory analysis will examine which decision cues
could explain these differences, and whether differential
reliance on these decision cues between groups explain
the group differences in accuracy. These decision cues will
then be further examined and purposely varied in the
Type 2 survey. For example, logistical concerns about
managing warfarin therapy may be more relevant to fam-
ily physicians than internists (who often are not responsi-
ble for long-term management), and might therefore
contribute to group differences. Systematic manipulation
of this cue in the Type 2 survey would reveal whether this
cue contributes to group differences in treatment deci-
sions.
Hypothesis five: some judgment inaccuracies will stem from 
physicians overweighting cues that are unrelated to treatment 
outcomes, and/or underweighting cues that are related to outcomes
This hypothesis will be evaluated using data from the
Type 2 surveys. The analytical approach is identical to that
described in hypothesis one, with the response variable
being "judged probability" instead of treatment decision.
This approach is conceptually inspired by lens modeling,
otherwise known as social judgment analysis [85-87]. The
approach involves systematically varying the levels of sev-
eral sources of information (cues) between a series of
vignettes. From these vignettes, the judgment strategies
employed by physicians when making their diagnoses can
be inferred. This judgment strategy can be represented as
a linear regression model, with standardized regression
weights describing the relative importance of each cue in
determining a physician's diagnosis. While the linear
model does not necessarily indicate what the physician
was thinking at the time of judgment, it will predict those
judgments accurately [88], and indicate which cues
affected judgment [89].
We will also tabulate the proportion of physicians for
whom one or more of the non-predictive variables have
coefficients different from zero, as assessed by the 95%
posterior probability region; this implies these variables
are used as predictors of either benefits or harms. We will
then tabulate the proportion of physicians using each spe-
cific type of variable to make their judgments.
For all regression models, we will employ graphical
approaches to look for outliers and influential observa-
tions, while statistics measuring model fit will also be cal-
culated. Steps to control the extent of missing data items
will be built into each aspect of the data collection and
data management process. During the final analysis of the
data we will rely on multiple imputation techniques to
handle the presence of missing data elements. We will
also compare the results to those obtained from the anal-
ysis based on complete cases only.
Sample size and power
Our survey response rate estimates are based on previous
similar work examining physicians' treatment decisions
for patients with HIV [74]. That study involved mailing a
Type 1 survey to a random sample of 2,495 physicians
from the American Medical Association master file. Simi-
lar methods to those planned for the current proposal
were used to enhance participation, including an honorar-
ium of $10 per physician. Of all surveys distributed, 3.8%
(96/2,495) were returned due to an incorrect address, and
2.6% (65/2,495) were returned because the physician had
retired. The final response rate for the eligible physicians
in this study was 51.4%. Given our plan to mail each sur-
vey to a minimum of 300 physicians, we expect 6% will
be ineligible, leaving 282 eligible. Of these, we expect at
least 50% will return completed surveys. Thus our
expected minimum total sample size will be 141 for each
survey. In the case of the warfarin surveys, we expect 141
family practitioners and 141 internal medicine specialists
to respond.
Hypothesis four will involve measuring the difference in
accuracy between two groups. Assuming a minimum crit-
ically important difference in accuracy of 0.5 standard
deviations, the power with a type one error rate of 5% and
141 physicians per group will be 0.98. As we will likely
need to adjust for some covariates in this comparison of
accuracy, some allowance needs to be anticipated. Previ-
ous simulation studies have suggested that adjusted anal-
yses should have at least 90% as much power as the
unadjusted models. Thus, we can expect to have at least
88.2% power (0.9 × 0.98 = 88.2%) [90].
Hypotheses one, three, and five involve prediction both
within and across physicians, but it is only in the latter
case where power becomes an issue, as statistical signifi-
cance of factors within a particular physician is not an
important issue in this study. Drawing on sample size
conventions for prediction [91] and taking physician as
the observation, we have chosen to estimate the number
of physicians needed on the basis of the number of
degrees of freedom (df) in the covariates that need to be
modelled. We propose to include gender (1 df), years of
experience (2 df), practice setting (2 df), volume of rele-
vant cases (1 df), current test ordering practice (1 df), and
previous experience with rare side effects (1 df). A total of
8 df multiplied by a rule of thumb fifteen observations per
degree of freedom [91] suggests we need at approximately
120 respondents; we expect 141. Hypothesis two involvesImplementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
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determining the percent of physicians that maintain
judged outcome likelihoods that have been ruled out by
95% confidence intervals from trials. The 95% percent
confidence interval for the percent of physicians based on
assuming maximum variance (p = .5) will be less than ±
1.96 × sqrt (0.25/141) = 0.082.
Discussion
We see this work as a necessary prerequisite for the devel-
opment and implementation of an intervention that will
increase the accuracy of judged outcome probabilities and
improve treatment utilization. In the next phase of this
work, we will use findings from this study to develop a
computerized feedback task designed to improve the
accuracy of these judgments. This study will tell us the
scope of the inaccuracies for our two clinical decisions,
determine a number of sources of these inaccuracies,
establish which physicians make which sorts of error, and
allow us to determine what kinds of feedback will be most
effective in improving judgment accuracy.
This work will be the first to assess in detail potential rea-
sons for physicians' suboptimal management of two very
important medical problems. It will be the first large-scale
study to examine the relationship between physician-spe-
cific judgment characteristics and medical decisions for
important, inappropriately treated clinical conditions. It
will also be the first to examine the accuracy of outcome
judgments for these clinical conditions, and to examine
whether they are affected by judgment heuristics and
biases.
We believe that the current proposal will have far-reaching
implications. It will provide insight as to why physicians
persistently use treatments inappropriately, despite clear
evidence about how they should be used. More impor-
tantly, this work will lead directly to the development of
focused interventions that could greatly improve treat-
ment utilization. For instance, the development of online
computer software that provides physicians with direct,
immediate feedback comparing their outcome probabil-
ity estimates to the best available evidence may lead to
substantial improvements in judged outcome probabili-
ties. While the question of whether such improvements
lead to improved treatment behaviour must be left to a
future full-scale RCT, the ground work proposed here will
allow us to determine whether developing such a tool to
be the focus of an RCT would be warranted.
It is likely that a wide variety of other treatment situations
are also affected by inappropriate outcome estimates. For
example, it is quite common to see over-utilization of
expensive, invasive, and/or high technology interven-
tions, such as percutaneous transluminal coronary angi-
oplasty (PTCA) [92], and screening for prostate cancer
with prostate specific antigen (PSA) assays [93,94], with-
out convincing evidence of the effectiveness of these inter-
ventions. The techniques proposed here will provide a
mechanism to understand the judgment processes that go
into the use of these interventions, and potentially to
increase appropriate use.
Limitations
Several study limitations warrant consideration. First, the
extent to which responses provided to these survey-based
vignettes reflect real-world management of patients in
actual practice is unclear. However, evidence is accumulat-
ing to support the validity of clinical case vignette-based
research. Physician decisions in response to case vignettes
generally mirror their decision making for simulated
patients with the same clinical problem. Furthermore, the
vignette approach approximates real-world decision mak-
ing much better than does data from standard chart
abstraction techniques [95-97]. We have carefully tried to
maximize the validity of our vignettes by 1) using
vignettes with high face validity; 2) allowing for responses
similar to those one might make in practice; 3) avoiding
"cueing" subjects by listing responses they are unlikely to
consider in real life; and 4) avoiding suggesting which
responses are expected.97 We will extensively pilot test
draft surveys to ensure that the vignettes are representative
of real-world decisions.
There is some possibility of significant response bias,
given that we have conservatively projected our response
rate to be 50%. This level of responding is consistent with
our experience with this type of survey [74], as well as
other similar surveys [98-100], while recent systematic
reviews have estimated similar overall mean response
rates to physician surveys [101,102]. There is evidence
that physicians who do not respond to mailed surveys are
less active in and knowledgeable about the relevant clini-
cal areas than those who do respond [103]. This might
mean that our results will understate the difficulties phy-
sicians have judging outcomes of the treatment of interest,
and the degree they use non-predictive variables to make
these judgments. However, any such response bias would
result in greater (not reduced) accuracy in judgments, and
therefore reduce the likelihood of supporting hypothesis
two, by yielding a conservative estimate of the extent to
which these physicians make inaccurate outcome judg-
ments.
Finally, it may be that some treatment decisions depend
as much on the value or importance placed on the out-
comes as they do on their likelihood. Evidence suggests
this may be true of patient decision making, where the
presence of vivid but rare potential side effects can have
disproportionate effects on decision making [104], and
may well be true of physician decision making as well. ForImplementation Science 2007, 2:18 http://www.implementationscience.com/content/2/1/18
Page 9 of 11
(page number not for citation purposes)
example, we have observed that treatment differences
between UK and US physicians deciding about drug ther-
apy for seizure patients may stem from differences in the
judged importance of particular side-effects. Indeed, some
have argued that for physicians "value is a consideration
in every decision representation" [13]. While methods of
measuring the values or importance of health outcomes-
called "utilities" in decision analysisexist, they are com-
plex and time-consuming; we therefore decided to limit
the scope of the current project to a consideration of
judged outcome likelihood.
Changes to the protocol after funding
This protocol has been peer-reviewed and approved for
funding by the Canadian Institutes of Health Research,
and has ethics approval from the Ottawa Hospital
Research Ethics Board. Our original proposal targeted use
of antibiotics for sore throat, and the use of HMG Co-A
reductase inhibitors (statins) for coronary artery disease
(CAD) and hypercholesterolemia. When detailed plan-
ning began after funding was received, the literature on
use of statins for CAD had grown more complex; it was
less clear whether statins are universally under-used, or
rather under-used in some populations and over-used in
others. This increasing complexity would have required us
to focus on a specific patient subgroup, making it more
difficult to find physician respondents that deal with the
specific group. We therefore decided to focus on anti-
coagulants for AF instead; methodology and analysis has
not changed.
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